New step towards tailor-made treatment for melanoma

Neoadjuvant immunotherapy has once again proven its power in patients with stage 3 melanoma, according to in Nature published results of the PRADO study.

The OpACIN neo study, the precursor to PRADO, had already shown that a combination of ipilimumab and nivolumab prior to lymph node surgery produced a high response rate of 77%, with acceptable side effects.

PRADO was primarily an extension of OpACIN-neo with 99 new patients. The researchers also decided to investigate whether follow-up treatment could be adjusted based on a patient’s response.

In patients with a very good response, extensive lymph node surgery was omitted, patients with a partial response were operated on, and patients with a poor response received surgery as well as follow-up treatment with immunotherapy or targeted therapy and possibly radiotherapy.

The results of the OpACIN neo study could be largely confirmed with PRADO. The response rate was almost as high (72%) and the side effects of the immunotherapy were acceptable. In addition, 61% of the patients had a very good response, without extensive lymph node surgery. This resulted in fewer side effects of the surgery and a better quality of life.


Anthony van Leeuwenhoek

Leave a Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Never miss any important news. Subscribe to our newsletter.